ISRCTN15733268已完成2 期
A double-blind placebo controlled crossover study to determine if melatonin can improve the length of day time sleep in subjects with transient misalignment of the sleep-wake cycle as a result of working permanent night-shifts
Alliance Pharmaceuticals Ltd (UK)0 个研究点目标入组 44 人开始时间: 2010年1月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects aged 18 to 65 years working permanent night-shifts with at least three consecutive night-shifts in their shift pattern
- •2. A female subject could be included if:
- •2.1. She was of non-child-bearing potential (e.g., post-menopausal for 1 year, had undergone bilateral tubal ligation, had undergone a hysterectomy or was physiologically incapable of becoming pregnant), or
- •2.2. She was of childbearing potential practising an acceptable method of birth control defined as the use of oral or depot hormonal contraception, an intrauterine contraceptive device or a combination of both spermicidal and barrier methods of contraception (a partner having had a vasectomy was not an acceptable reason for inclusion), or
- •2.3. Total abstinence from sexual intercourse was maintained
- •3. Provided written informed consent
- •4. No planned absences from work, other than rest days, for the duration the subject was in the study. Subjects could work additional night-shifts as overtime
排除标准
- •1. Clinically significant unstable medical abnormality, chronic disease or history or presence of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, psychiatric, metabolic disease or malignancy or other clinically relevant abnormality which in the opinion of the Investigator would preclude successful participation in the study
- •2. A recent history (less than 2 years) of alcohol or drug abuse or current evidence of substance dependence or abuse as defined by Diagnostic and Statistical Manual of Mental Disorders-IV criteria, with the exception of nicotine dependence
- •3. Female subjects who were pregnant, not using an adequate form of contraception or breast-feeding
- •4. Subjects receiving vitamins B6 and B12 supplements (excluding multivitamin supplements at recommended dose)
- •5. Subjects with a known hypersensitivity to melatonin or any of the excipients in the formulation
- •6. Subjects receiving hypnotics, tricyclic antidepressants, monoamine oxidase inhibitors, serotonin reuptake inhibitors, lithium, beta-blockers, calcium channel blockers, central alpha-blockers, non-steroidal anti-inflammatory drugs (excluding occasional over-the-counter use), alprazolam, triazolam, neuroleptics, or barbiturates. Subjects receiving any of these compounds were eligible for entry provided the medication was stopped 2 weeks prior to study entry.
- •7. Subjects with a known history of impaired hepatic or renal function defined as transaminases greater than 2 x the upper limit of normal or creatinine clearance of less than 35 mL/min
- •8. Subjects with a known severe allergic or auto-immune disease (e.g., multiple sclerosis, rheumatoid arthritis, severe asthma and systemic lupus erythematosus)
- •9. Subjects who had received an experimental drug within the previous 3 months
- •10. Subjects using melatonin
- •11. Subjects, who, by virtue of the need to care for close family members, might have been subjected to intermittent disturbance during their daytime rest periods
- •12. Subjects who, in the opinion of the Investigator, were not capable of completing the study
- •13. Subjects who did not consent to their General Practitioner being informed of their participation in the study
- •Pregnant or breast feeding women were excluded as the preclinical data on melatonin in this group were not available at the start of the study. Subjects were advised that caution should be exercised when driving or operating any heavy or dangerous machinery within 6 hours of taking a dose of study medication.
研究者
相似试验
已完成
2 期
1.5 versus 3.0 mg APL510 to normalise sleep patterns in elderly subjects with insomniaMental and Behavioural DisordersNonorganic sleep disordersInsomniaISRCTN82088636Alliance Pharmaceuticals Ltd (UK)80
进行中（未招募）
1 期
A double-blind placebo controlled cross-over study to determine if 1.5 and 3mg of APL510 can normalise sleep patterns in elderly subjects with difficulty in maintenance of sleep and/or initiating sleep onset. - N/AEUCTR2004-003939-32-GBAlliance Pharmaceuticals Ltd80
进行中（未招募）
不适用
A double blind placebo controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in adult patients with attention deficit hyperactivity disorder - Effects of atomoxetine on attention and driving in adult ADHDThe effects of atomoxetine on driving performance, attention and response inbihition are studied in adult patients with attention-deficit hyperactivity disorderEUCTR2007-001855-20-NLFaculty of Social Sciences, Utrecht University30
撤回
不适用
A double blind placebo-controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in adult patients with attention-deficit hyperactivity disorderADHD10009841Attention Deficit Hyperactivity DisorderNL-OMON31557niversiteit Utrecht30
进行中（未招募）
1 期
A double-blind placebo-controlled cross-over study to determine if melatonin can improve the length of day time sleep in subjects with transient misalignment of the sleep-wake cycle as a result of working permanent night shifts.Transient misalignment of the sleep-wake cycle as a result of working night shifts (insomnia in night shift workers)EUCTR2005-000120-17-GBAlliance Pharmaceuticals Ltd60